Risk factors of persistent disease at 5 years from diagnosis in differentiated thyroid cancer: study of 63 patients;Factores relacionados con la persistencia de la enfermedad a los 5 años del diagnóstico de cáncer diferenciado de tiroides: estudio de 63 pacientes

Endocrinologia y Nutricion

Volumn 56, Issue 7, 2009, Pages 361-368

  Familiar, Cristina ^a   Moraga, Inmaculada ^a   Antón, Teresa ^a   Gargallo, Manuel ángel ^b   Ramos, Araceli ^a   Marco, Ángel luis ^a   Villa, Mariano ^a   Tapia, María ángeles ^a  

^a HOSPITAL DE MÓSTOLES   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

Author keywords

Differentited thyroid cancer; Recurrence; Stimulated thyroglobulin

Indexed keywords

THYROGLOBULIN;

ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; THYROID CANCER; THYROIDECTOMY;

EID: 70350449593     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(09)72455-6     Document Type: Article

References (63)

1. Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada. Public Health Agency of Canada. Canadian Cancer Statistics; 2005. Disponible en: http://www.cancer.ca
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thum M.J. Cancer Statistics 2007. CA Cancer J Clin 57 (2007) 43-66
3. Hodgson N.C., Button J., and Solorzano C.C. Thyroid Cancer: is the incidence still increasing?. Ann Surg Oncol 11 (2004) 1093-1097
4. Baudin E., Travagli J.P., Ropers J., Mancusi F., Bruno-Brossi G., Caillou B., et al. Microcarcinoma of the thyroid gland. Cancer 83 (1998) 553-559
5. a ed. New York: Springer-Verlag; 2002.
6. Sherman S.I., Brierley J.D., Sperling M., Ain K.B., Bigos S.J., Cooper D.S., et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry group. Cancer 83 (1998) 1012-1021
7. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12 (2002) 583-590
8. Torlontano M., Attard M., Crocetti U., Tumino S., Bruno R., Costante G., et al. Follow-up of low-risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89 (2004) 3402-3407
9. Harvey R., Matheson N., Gabowski P., and Rodger A. Measurement of serum thyroglobulin is of value in detecting tumor recurrence following treatment of differentiated thyroid carcinoma by lobectomy. Br J Surg 77 (1990) 324-326
10. Grebe S.K.G. Diagnosis and management of thyroid carcinoma. Expert Rev Endocrinol 4 (2009) 25-43
11. 131). Ann Surg 219 (1994) 587-595
12. Ortiz R., Rodriguez J.M., Parilla P., Perez D., Moreno-Gallego A., and Rios A. Recurrent papillary thyroid cancer:analysis of prognostical factors including the histological variant. Eur J Surg 167 (2001) 406-412
13. Tuttle R.M., and Leboeuf R. Follow-up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 37 (2008) 419-435
14. Hedinger C., Williams E.D., and Sobin L.H. Histological typing of thyroid tumours. International histological classification of tumours, n.° 11 (1998), World Health Organization, Geneva p. 1-18
15. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W.A., Wiersinga W., and European Thyroid Cancer Task force. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 (2006) 787-803
16. Tuttle R.M., Leboeuf R., and Martorella A.J. Papillary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin North Am 36 (2007) 753-778
17. Martins R.G., Caplan R.H., Lambert P.J., Roomey B., and Kisken W.A. Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center, 1969-1995. J Am Coll Surg 185 (1997) 388-397
18. Samaan N.A., Schultz P.N., Hickey R.C., Goepfert H., Haynie T.P., Johnston D.A., et al. The results of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 73 (1992) 714-720
19. Mazzaferri E.L., Robbins R.J., Braverman L.E., Pacini F., Haugen B., Wartofsky L., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma [carta]. J Clin Endocrinol Metab 88 (2003) 4508-4509
20. Grigsby P.W., Baglan K., and Siegel B.A. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 85 (1999) 945-951
21. David A., Blotta A., Rossi R., Zatelli M.C., Bondanelli M., Roti E., et al. Clinical value of different responses of thyroid thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 15 (2005) 267-273
22. Schlumberger M., Berg G., Cohen O., Duntas L., Jamar F., Jarzab B., et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150 (2004) 105-112
23. Eustatia-Rutten C.F., Smit J.W., Romijn J.A., Van der Kleij-Corssmit E.P., Pereira A.M., Stokkel M.P., et al. Diagnostic value of serum thyroglobulin measurement in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol 61 (2004) 61-74
24. Lubin E., Mechlis-Frish S., Zatz S., Shimoni A., Segal K., Avraham A., et al. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastasic differentiated thyroid carcinoma. J Nucl Med 35 (1994) 257-262
25. Sanders L.E., and Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133 (1998) 419-425
26. Tissell L.E., Nilsson B., Molne J., Hansson G., Fjalling M., Jansson S., et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 20 (1996) 854-859
27. Loh K.C., Greenspan F.S., Gee L., Miller T.R., and Yeo P.P. Pathological tumor-node-metastasis (pTNM) for papillary and follicular thyroid carcinoma: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82 (1997) 3353-3362
28. Shaha A.R., Shah J.P., and Loree T.R. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 3 (1996) 534-538
29. Segal K., Raveh E., Lubin E., Abraham A., Shvero J., and Feinmesser R. Well-differentiated thyroid carcinoma. Am J Otolaryngol 17 (1996) 401-406
30. Jensen M.H., Davis R.K., and Derriak L. Thyroid cancer: a computedassisted review of 5287 cases. Otolaryngol Head Neck Surg 102 (1990) 51-65
31. Lang B.H., Lo C.Y., Chan W.F., and Lan K.Y. Prognostic factors in papillar and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol 14 (2007) 730-738
32. Kim S., Wei J.P., Braverman J.M., and Brams D.M. Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 139 (2004) 390-394
33. Mazzaferri E.L., and Young R.L. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 70 (1981) 511-518
34. Goepfert H., Dichtel W.J., and Samaan N.A. Thyroid cancer in children and teenagers. Arch Otolaryngol Head Neck Surg 110 (1984) 72-75
35. Chow S.M., Law S.C., Au S.K., Leung T.W., Chang P.T., Mendenhall W.M., et al. Differentiated thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy: comparison between papillary and follicular carcinoma in a single institute. Head Neck 24 (2002) 670-677
36. Marchesi M., Biffoni M., Biancori F., Berni A., and Campana F.P. Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma. Eur J Surg 588 Suppl (2003) 46-50
37. Tennvall J., Biörklund A., Möller J., Ranstam J., and Akerman M. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma?. Cancer 57 (1986) 1405-1414
38. Akslen L.A., and Livolsi V.A. Prognostic significance of histologic grading compared with classification of papillary thyroid cancer. Cancer 15 (2000) 1902-1908
39. DeGroot L.J., Kaplan E.L., McCormick M., and Straus F.H. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71 (1990) 414-424
40. Chow S.M., Law S.C.K., and Au S.K. Changes in clinical presentation, management and outcome in 1348 patients with differentiated cancer: experience in a single institute in Hong Kong 1960-2000. Clin Oncol 15 (2003) 329-336
41. Shaha A.R., Loree T.R., and Sha J.P. Prognostic factors and risk group analysis of follicular carcinoma of the thyroid. Surgery 118 (1995) 1136-1138
42. Links T.P., Van Tol K.M., Jager P.L., Plukker J.J.H.M., Piers D.A., Boezen H.M., et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 12 (2005) 272-280
43. Eustatia-Rutten C.F.A., Corssmit E.P., Biersmasz N.R., Pereira A.M., Romijn J.A., and Smit J.W. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 91 (2006) 313-319
44. Gardner R.E., Tuttle R.M., Burman K.D., Haddady S., Truman C., Sparling Y.H., et al. Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 126 (2000) 309-312
45. Katoh R.H., Sasaki J., Kurihara H., Suzuki K., Lida Y., and Kawaoi A. Multiple thyroid involvement (intraglandular metastases) in papillary thyroid cancer. A clinicopathologic study of 105 consecutive patients. Cancer 70 (1992) 1585-1590
46. Hay I.D. Papillary thyroid carcinoma. Endocrinol Clin North Am 19 (1990) 545-576
47. Scheumann G.F., Gimm O., Wegener G., Hundeshagen H., and Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18 (1994) 559-568
48. Qubain S.W., Nakano S., Baba M., Takao S., and Aiken T. Distribution of lymph node micrometastases in no well-differentiated thyroid carcinoma. Surgery 131 (2002) 249-256
49. Gimm O., Rath F.W., and Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg 85 (1998) 252-256
50. Grebe S.K., and Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin North Am 5 (1996) 43-63
51. Gemsenjäger E., Perren A., Seifert B., Schüller G., Schweizer I., and Heitz P.V. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 197 (2003) 182-190
52. Lundgren C.I., Hall P., Dickman P.W., and Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 106 (2006) 523-531
53. Rouxel A., Hejblum G., Bernier M.O., Boëlle P.Y., Ménégaux F., Mansour G., et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 89 (2004) 5362-5368
54. Pacini F., Capezzone M., Elisei R., Ceccarelli C., Taddei D., and Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have indetectable stimulated serum thyroglobulin levels after initial treatment. J Clin Endocrinol Metab 87 (2008) 1499-1501
55. Toubeau M., Touzery C., Arveux P., Chaplain G., Vaillant G., Berriolo A., et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after I131 ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 45 (2004) 988-994
56. Roelants V., Nayer P.D., Bouckaert A., and Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24 (1997) 722-727
57. Hall F.T., Beasley N.J., Eski S.J., Witterick I.J., Walfish P.G., and Freeman J.L. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 113 (2003) 77-81
58. Ronga G., Filesi M., Ventroni G., Vetri A.R., and Signore A. Value of the first thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 26 (1999) 1448-1452
59. Pacini F., Agate L., Elisei R., Ceccarelli C., Lippi F., Molinaro E., et al. Outcome of differentiated thyroid cancer with detectable serum thyroglobulin and negative diagnostic 131 I whole body scan: a comparison of patients treated with high 131 I activities versus untreated patients. J Clin Endocrinol Metab 86 (2001) 4092-4097
60. Cailleux A.F., Baudin E., Travagli J.P., Ricard M., and Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?. J Clin Endocrinol Metab 85 (2000) 175-178
61. Kim T.Y., Kim W.B., Kim E.S., Ryu T.S., Hong S.J., and Shon Y.K. Serum thyroglobulin levels at the time of 131 I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90 (2005) 1440-1445
62. Baudin E., Do Cao C., Cailleux A.F., Leboulleux S., Travagli J.P., and Schlumberger M. Positive predictive value of serum thyroglobulin levels measured during the first year of follow-up after thyroid hormone withdrawal in thyroid cancer patients. J Clin Endocrinol Metab 88 (2003) 1107-1111
63. Torlontano M., Crocetti U., D'Aloiso L., Bonfitto N., Di Giorgio A., Modoni S., et al. Serum thyroglobulin and 131 I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 148 (2003) 19-24